significantTreatment update
Ibrutinib + venetoclax fixed-duration combination in treatment-naive WM
Waldenström's Macroglobulinemia →Summary
Castillo et al. (Blood 2024) reported results of a novel fixed-duration ibrutinib + venetoclax combination in treatment-naive WM. This approach aims to achieve deep responses with time-limited therapy, avoiding the indefinite BTK inhibitor treatment paradigm. Represents a shift toward combination strategies seeking MRD negativity.
Related treatments
More from Waldenström's Macroglobulinemia
incrementalTreatment update
Emerging CAR-T and bispecific antibody approaches for WM
incrementalNew research
BTK degraders (PROTACs) enter clinical trials for B-cell malignancies
significantTreatment update
Pirtobrutinib shows activity in covalent BTK inhibitor-pretreated WM
incrementalNew research
Genomics-guided treatment selection advances in WM
ID: waldenstroms-macroglobulinemia-update-2Type: treatment_updateImpact: significant